BRIEF-Aveo Pharmaceuticals announces dosing of first patient in Phase 3 tivo-3 study of tivozanib in renal cell carcinoma
May 26, 2016 at 08:14 AM EDT
* Announces dosing of first patient in pivotal Phase 3 tivo 3 study of tivozanib in renal cell carcinoma